2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
AMPA receptor[1]
In Vivo
NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion[1]. NBQX provides potent anticonvulsant protection against AMPA. The ED50 values for the protection against AMPA-induced seizures by NBQX (30 min, i.p.) is 23.6 (11.6- 48.0)[2].
In Vitro
NBQX has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex[1].
Kinase Assay
Cell Assay
Animal Administration
Rats[1] Male Sprague-Dawley rats weighing 350-390 g are used for study. 30 mg/kg of NBQX (2x15 mg/mL) is administered i.v. as a bolus dose followed by an infusion of 10 mg/kg/h for 4 h, the bolus dose and infusion are started immediately after MCA occlusion. Blood samples are taken from these animals at 1, 2, 3 and 4 h after the start of the infusion and the plasma level of NBQX in each sample is measured[1]. Mice[1] The time course for the anticonvulsant action of NBQX and of GYKI 52466 against AMPA-induced seizures is determined by pretreating groups (n=10) of Swiss mice with 30 and 60/zmol/kg NBQX or GYKI 52466 (i.p.) 15-120 min before challenging the mice with a convulsant dose of AMPA (5 nmol) i.c.v[2].
References
[1]. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
